Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment

Marzio E E Sabbioni, Hans Peter Siegrist, Marisa Bacchi, Jürg Bernhard, Monica Castiglione, Beat Thürlimann, Hervé Bonnefoi, Lucien Perey, Richard Herrmann, Aron Goldhirsch, Christoph Hürny

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective: The association of known prognostic factors with immune cell counts and β2-microglobulin and soluble IL-2 receptor (sIL-2r) serum levels as markers of activation of the immune system was investigated in breast cancer. Methods: Two hundred thirty five operated stage I and II breast cancer patients to receive adjuvant treatment in IBSCG trials were assessed in a cross-sectional study immediately before the first treatment. Leukocytes, lymphocytes and lymphocyte subset counts, β2-microglobulin and sIL-2r serum levels were assessed as immunological parameters. Prognostic factors were tumor load, receptor status, patient characteristics, and contextual factors of the immune assessment (such as time of the day, time since surgery, type of surgery, concomitant medication, co-morbidity). Results: In an operated early stage breast cancer patient population, tumor load was not associated with immune cell counts, βn2-microglobulin, or sIL-2r before adjuvant treatment. There was a pattern of association of prognostically favorable factors such as estrogen receptor (ER) positive tumor and older age with higher NK cell counts or with β2-microglobulin or sIL-2r. In addition, immune cell counts and the markers of activation of the immune system were affected by several contextual factors, such as diurnal variability, time since surgery, type of surgery, and the intake of concomitant medication. Conclusions: The association of NK cell counts and β2-microglobulin or sIL-2r serum levels with prognostically favorable factors such as ER positive tumor and older age supports the assumption that the immune system plays a role in the course of early breast cancer. The exact nature of this role requires further study.

Original languageEnglish
Pages (from-to)279-287
Number of pages9
JournalBreast Cancer Research and Treatment
Volume59
Issue number3
DOIs
Publication statusPublished - 2000

Fingerprint

Interleukin-2 Receptors
Immunity
Cell Count
Breast Neoplasms
Immune System
Tumor Burden
Natural Killer Cells
Estrogen Receptors
Serum
Therapeutics
Lymphocyte Subsets
Lymphocyte Count
Immunologic Factors
Neoplasms
Leukocytes
Cross-Sectional Studies
Lymphocytes
Morbidity
Population

Keywords

  • β2-microglobulin
  • Breast cancer
  • Cellular immunity
  • Prognosis
  • SIL-2r

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sabbioni, M. E. E., Siegrist, H. P., Bacchi, M., Bernhard, J., Castiglione, M., Thürlimann, B., ... Hürny, C. (2000). Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment. Breast Cancer Research and Treatment, 59(3), 279-287. https://doi.org/10.1023/A:1006379925343

Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment. / Sabbioni, Marzio E E; Siegrist, Hans Peter; Bacchi, Marisa; Bernhard, Jürg; Castiglione, Monica; Thürlimann, Beat; Bonnefoi, Hervé; Perey, Lucien; Herrmann, Richard; Goldhirsch, Aron; Hürny, Christoph.

In: Breast Cancer Research and Treatment, Vol. 59, No. 3, 2000, p. 279-287.

Research output: Contribution to journalArticle

Sabbioni, MEE, Siegrist, HP, Bacchi, M, Bernhard, J, Castiglione, M, Thürlimann, B, Bonnefoi, H, Perey, L, Herrmann, R, Goldhirsch, A & Hürny, C 2000, 'Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment', Breast Cancer Research and Treatment, vol. 59, no. 3, pp. 279-287. https://doi.org/10.1023/A:1006379925343
Sabbioni, Marzio E E ; Siegrist, Hans Peter ; Bacchi, Marisa ; Bernhard, Jürg ; Castiglione, Monica ; Thürlimann, Beat ; Bonnefoi, Hervé ; Perey, Lucien ; Herrmann, Richard ; Goldhirsch, Aron ; Hürny, Christoph. / Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment. In: Breast Cancer Research and Treatment. 2000 ; Vol. 59, No. 3. pp. 279-287.
@article{b5712a8909a24470b87c74c402fc0293,
title = "Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment",
abstract = "Objective: The association of known prognostic factors with immune cell counts and β2-microglobulin and soluble IL-2 receptor (sIL-2r) serum levels as markers of activation of the immune system was investigated in breast cancer. Methods: Two hundred thirty five operated stage I and II breast cancer patients to receive adjuvant treatment in IBSCG trials were assessed in a cross-sectional study immediately before the first treatment. Leukocytes, lymphocytes and lymphocyte subset counts, β2-microglobulin and sIL-2r serum levels were assessed as immunological parameters. Prognostic factors were tumor load, receptor status, patient characteristics, and contextual factors of the immune assessment (such as time of the day, time since surgery, type of surgery, concomitant medication, co-morbidity). Results: In an operated early stage breast cancer patient population, tumor load was not associated with immune cell counts, βn2-microglobulin, or sIL-2r before adjuvant treatment. There was a pattern of association of prognostically favorable factors such as estrogen receptor (ER) positive tumor and older age with higher NK cell counts or with β2-microglobulin or sIL-2r. In addition, immune cell counts and the markers of activation of the immune system were affected by several contextual factors, such as diurnal variability, time since surgery, type of surgery, and the intake of concomitant medication. Conclusions: The association of NK cell counts and β2-microglobulin or sIL-2r serum levels with prognostically favorable factors such as ER positive tumor and older age supports the assumption that the immune system plays a role in the course of early breast cancer. The exact nature of this role requires further study.",
keywords = "β2-microglobulin, Breast cancer, Cellular immunity, Prognosis, SIL-2r",
author = "Sabbioni, {Marzio E E} and Siegrist, {Hans Peter} and Marisa Bacchi and J{\"u}rg Bernhard and Monica Castiglione and Beat Th{\"u}rlimann and Herv{\'e} Bonnefoi and Lucien Perey and Richard Herrmann and Aron Goldhirsch and Christoph H{\"u}rny",
year = "2000",
doi = "10.1023/A:1006379925343",
language = "English",
volume = "59",
pages = "279--287",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment

AU - Sabbioni, Marzio E E

AU - Siegrist, Hans Peter

AU - Bacchi, Marisa

AU - Bernhard, Jürg

AU - Castiglione, Monica

AU - Thürlimann, Beat

AU - Bonnefoi, Hervé

AU - Perey, Lucien

AU - Herrmann, Richard

AU - Goldhirsch, Aron

AU - Hürny, Christoph

PY - 2000

Y1 - 2000

N2 - Objective: The association of known prognostic factors with immune cell counts and β2-microglobulin and soluble IL-2 receptor (sIL-2r) serum levels as markers of activation of the immune system was investigated in breast cancer. Methods: Two hundred thirty five operated stage I and II breast cancer patients to receive adjuvant treatment in IBSCG trials were assessed in a cross-sectional study immediately before the first treatment. Leukocytes, lymphocytes and lymphocyte subset counts, β2-microglobulin and sIL-2r serum levels were assessed as immunological parameters. Prognostic factors were tumor load, receptor status, patient characteristics, and contextual factors of the immune assessment (such as time of the day, time since surgery, type of surgery, concomitant medication, co-morbidity). Results: In an operated early stage breast cancer patient population, tumor load was not associated with immune cell counts, βn2-microglobulin, or sIL-2r before adjuvant treatment. There was a pattern of association of prognostically favorable factors such as estrogen receptor (ER) positive tumor and older age with higher NK cell counts or with β2-microglobulin or sIL-2r. In addition, immune cell counts and the markers of activation of the immune system were affected by several contextual factors, such as diurnal variability, time since surgery, type of surgery, and the intake of concomitant medication. Conclusions: The association of NK cell counts and β2-microglobulin or sIL-2r serum levels with prognostically favorable factors such as ER positive tumor and older age supports the assumption that the immune system plays a role in the course of early breast cancer. The exact nature of this role requires further study.

AB - Objective: The association of known prognostic factors with immune cell counts and β2-microglobulin and soluble IL-2 receptor (sIL-2r) serum levels as markers of activation of the immune system was investigated in breast cancer. Methods: Two hundred thirty five operated stage I and II breast cancer patients to receive adjuvant treatment in IBSCG trials were assessed in a cross-sectional study immediately before the first treatment. Leukocytes, lymphocytes and lymphocyte subset counts, β2-microglobulin and sIL-2r serum levels were assessed as immunological parameters. Prognostic factors were tumor load, receptor status, patient characteristics, and contextual factors of the immune assessment (such as time of the day, time since surgery, type of surgery, concomitant medication, co-morbidity). Results: In an operated early stage breast cancer patient population, tumor load was not associated with immune cell counts, βn2-microglobulin, or sIL-2r before adjuvant treatment. There was a pattern of association of prognostically favorable factors such as estrogen receptor (ER) positive tumor and older age with higher NK cell counts or with β2-microglobulin or sIL-2r. In addition, immune cell counts and the markers of activation of the immune system were affected by several contextual factors, such as diurnal variability, time since surgery, type of surgery, and the intake of concomitant medication. Conclusions: The association of NK cell counts and β2-microglobulin or sIL-2r serum levels with prognostically favorable factors such as ER positive tumor and older age supports the assumption that the immune system plays a role in the course of early breast cancer. The exact nature of this role requires further study.

KW - β2-microglobulin

KW - Breast cancer

KW - Cellular immunity

KW - Prognosis

KW - SIL-2r

UR - http://www.scopus.com/inward/record.url?scp=0034093818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034093818&partnerID=8YFLogxK

U2 - 10.1023/A:1006379925343

DO - 10.1023/A:1006379925343

M3 - Article

C2 - 10832598

AN - SCOPUS:0034093818

VL - 59

SP - 279

EP - 287

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -